Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab After ASCT in Relapsed/Refractory Lymphoma
NCT02362997Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2015
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), classical Hodgkin lymphoma (cHL) and peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-free Survival After ASCT at 18 months. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)classical Hodgkin lymphoma (cHL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02362997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362997.